Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1189-1195, Vol. 8, No. 6
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.6.1189-1195.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Circulating Inflammatory Mediators in Patients with
Fever: Predicting Bloodstream Infection
A. B. Johan
Groeneveld,1,*
Ailko W. J.
Bossink,1
Gerard J.
van
Mierlo,2 and
C. Erik
Hack2
Medical Intensive Care Unit of the Department
of Internal Medicine, Academisch Ziekenhuis Vrije
Universiteit,1 and Central Laboratory of
The Netherlands Red Cross Blood Transfusion
Service,2 Amsterdam, The Netherlands
Received 9 March 2001/Returned for modification 1 June
2001/Accepted 27 July 2001
 |
ABSTRACT |
The systemic host response to microbial infection involves clinical
signs and symptoms of infection, including fever and elevated white
blood cell (WBC) counts. In addition, inflammatory mediators are
released, including activated complement product C3a, interleukin 6 (IL-6), and the acute-phase reactant secretory phospholipase A2 (sPLA2). To compare the value of the latter
with the former in predicting (the degree of) microbial infection at
the bedside, we determined clinical variables and took blood samples
daily for 3 consecutive days in 300 patients with a new fever
(>38.0°C rectally or >38.3°C axillary). Microbiological culture
results for 7 days after inclusion were collected. Patients were
divided into clinical and microbial categories: those without and with a clinical focus of infection and those with negative cultures, with
positive local cultures or specific stains for fungal
(n = 13) or tuberculous infections
(n = 1), and with positive blood cultures,
including one patient with malaria parasitemia. The area under the
curve (AUC) of the receiver operating characteristic (ROC) for
prediction of positive cultures was 0.60 (P < 0.005) for peak temperature and 0.59 (P < 0.01)
for peak WBC count, 0.60 (P < 0.005) for
peak C3a, 0.63 (P < 0.001) for peak IL-6, and 0.61 (P < 0.001) for peak sPLA2. The AUC
under the ROC curve for prediction of positive blood cultures was 0.68 (P < 0.001) for peak temperature and 0.56 for peak
WBC count (P < 0.05). The AUC for peak C3a was
0.69, that for peak IL-6 was 0.70, and that for sPLA2 was
0.67 (for all, P < 0.001). The degree of microbial
invasion is thus a major determinant of the clinical and inflammatory
host response in patients with fever. Moreover, circulating
inflammatory mediators such as C3a and IL-6 may help to predict
positive blood cultures, together with clinical signs and symptoms of
the host response to microbial infection, even before culture results
are available. This may help in the designing of entry criteria for therapeutic intervention studies.
 |
INTRODUCTION |
Fever is considered to be
clinical evidence for inflammation, mostly caused by microbial
infection, at least in patients (22). The criteria of
systemic inflammatory response syndrome (SIRS), which may predict
microbial infection, are fever and elevated white blood cell (WBC)
counts, while the SIRS criteria tachypnea and tachycardia may be
nonspecific and too sensitive for microbial infection (2-5,
33). Hence, authors have searched, with varying success, for
other objective predictors of the host response to microbial infection
(2-5, 33). This may help to identify patients who may
benefit most from immunomodulating therapies of sepsis, trials that
have failed so far in heterogeneous patient populations with sepsis
(1). Prediction of microbial bloodstream infection at an
early stage would be particularly helpful since this may carry a
mortality rate of 30% or more, if treated inappropriately or too late
(21, 33).
The host response to microbial infection is thought to be mediated by
the release of inflammatory substances that may help the host to
eradicate the invading organisms. During a local infection and host
response, the release may be confined to the affected tissue, while a
systemic infection and host response may be associated with release of
inflammatory mediators into the bloodstream (10, 19, 31).
Therefore, circulating inflammatory mediators have been suggested to be
predictive for a systemic microbial infection and for a poor outcome,
in patients with fever (5). In surgical and emergency
departments and in critically ill febrile patients and neonates,
relatively small studies indeed have suggested some predictive value
for systemic microbial infection and its severity of C3a, a product of
complement activation; of interleukin 6 (IL-6), the alarm
cytokine, as an indicator of an activated host defense; and of
the acute-phase reactant secretory phospholipase
A2 (sPLA2), believed to be
produced in response to IL-6 in the liver, among others (8, 9,
13, 20, 26-29). The factors may be superior to the commonly
used acute-phase reactant C1-reactive protein (CRP) in predicting microbial infection (9, 13, 20, 26, 27). Moreover, systemically elevated mediators of the primary nonspecific host response to microbial infection, including circulating activated complement products, cytokines (IL-6) and
sPLA2, are of prognostic value, during
established sepsis and septic shock (6-8, 11, 12, 14-18,
23-25, 29, 30, 32).
To compare the relative value of circulating inflammatory variables
versus clinical variables of the systemic host response in predicting
microbial infection locally and in the bloodstream, at an early stage
when results of microbiological studies are not yet available, we
evaluated a large cohort of febrile patients in whom circulating levels
of C3a, IL-6, and sPLA2 were measured serially.
We have chosen these factors because of interrelationships in the
primary nonspecific host response to microbial infection (12, 14,
32).
 |
MATERIALS AND METHODS |
During a 1-year period a total of 300 consecutive
patients with newly onset fever (body temperature of
38.0°C
axillary or
38.3°C rectal), admitted to the Department of Internal
Medicine in a university hospital, were included in the study (4,
5). Two hundred eighty-four patients had SIRS and 200 had
sepsis, i.e., SIRS and a clinical focus of infection, but of the SIRS criteria involved, only temperature and WBC counts contributed to
prediction of positive (blood) cultures (4, 5). The study had been approved by the local committee on ethics. All patients or
their closest relatives gave informed consent before inclusion. Exclusion criteria were pregnancy; use of cytokines potentially interfering with host defense, e.g., administration of gamma interferon and IL-2; treatment for malignant hematological disease; shock; and a
life expectancy of less than 24 h.
At inclusion, data on variables that could affect culture
results and levels of inflammatory mediators were recorded,
including age, gender, known infection with human immunodeficiency
virus or presence of AIDS, known malignancies, known diabetes mellitus, prior treatment with immunocompromising (cytostatic and steroidal) drugs and antibiotics, and the estimated time elapsed between onset of
fever and inclusion. We further estimated the time elapsed between
hospital admission and onset of fever. Patients admitted into the
hospital more than 72 h before onset of fever were considered to
suffer from nosocomial fever. A potential focus was searched for by the
treating physician on the basis of clinical examination and appropriate
imaging techniques, and a clinical focus of infection was diagnosed
according to the results. Patients were monitored until day 28 for
outcome, and patients discharged within this period were considered to
be survivors. We only considered death potentially related to the
febrile episode, thereby excluding five patients in whom fever had
resolved and who ultimately died from apnea following aspiration
(n = 1), cardiac arrest in metastatic malignant disease
(n = 2), cardiogenic shock following cardiomyopathy (n = 1), and respiratory insufficiency following
cervical cord dissection (n = 1).
Microbial cultures.
At least two blood samples for culture
were obtained by venipuncture at inclusion. Supplementary blood for
culture was collected when clinically indicated. Local specimens for
culture were collected, depending on the clinical focus of infection.
All local and blood culture results during a follow-up period of 7 days
after inclusion were recorded. Blood for culture was processed using
delayed vial entry bottles for aerobic and anaerobic cultures and
Bactec 9120 and 9240 automatic analyzers (Becton Dickinson,
Erembodegem, Belgium). Bottles were incubated for a maximum of 7 days.
If the analyzers showed growth, Gram stains were prepared and
identification and sensitivity cultures were processed. Blood cultures
containing Staphylococcus epidermidis were considered
contaminated if only one bottle revealed growth and there were no
indwelling vascular catheters. Local specimens were processed using
standardized procedures, including Gram staining, culture, and
sensitivity tests, and specific stains were performed, if indicated, to
document fungal (n = 13) or tuberculous infections
(n = 1). Positive local microbiological results were
thought to reflect infection as opposed to colonization if the treating
physician decided to prescribe or continue antimicrobial therapy based
on these results.
Blood sampling.
We obtained at inclusion and daily
thereafter for two consecutive days (days 1, 2, and 3) blood samples
for determination of WBC counts (Sysmec [Kolbe, Japan] SE 9000 analyzer). The samples for mediator levels were collected in tubes
containing soybean trypsin inhibitor (final concentration, 100 µg/ml), EDTA (10 mmol/liter), and benzamidine (10 mmol/liter), to
prevent in vitro activation. All tubes were centrifuged for 10 min at
2,750 rpm (Rotixo 120R; Hettich Zentrifugen, Tuttlingen,
Germany), and the plasma was stored immediately at
70°C
until assays were performed. To determine normal levels in plasma,
blood was obtained from healthy laboratory personnel under similar conditions.
Assays.
Complement activation in the patients was measured
by assessing circulating levels of C3a with a radioimmunoassay as
described before (17). In this test binding of
125I-labeled C3 to anti-C3a antibodies
immobilized onto a solid phase (Sepharose) was inhibited by C3a present
in plasma samples. To prevent interference by native C3, plasma samples
were first precipitated with 11% (wt/vol) polyethylene glycol 6000, after which the supernatant was tested. Results were expressed as
nanomoles per liter. Normal values in healthy volunteers are less than
or equal to 5 nmol/liter. The lower limit of detection is 1 nmol/liter.
IL-6 in plasma was measured by an enzyme-linked immunosorbent assay
(ELISA) as described before (21). Briefly, the ELISA
plates were coated with the monoclonal antibody CLB. IL-6 and plasma
samples were incubated on these plates. After a washing procedure,
bound IL-6 was detected by incubation with biotinylated sheep
antibodies against IL-6, after which plates were incubated with
streptavidin-polymerized horseradish peroxidase. Finally, the plates
were developed with 3,5,3',5'-tetramethyl benzidine. Results were
related to a dose-response curve obtained with recombinant human IL-6
and expressed as picograms per milliliter. Normal values in healthy
volunteers are less than 10 pg/ml. The lower limit of detection is 3 pg/ml. Antigen levels of secretory nonpancreatic type II
(sPLA2) were assessed with help of an ELISA. Two
different monoclonal antibodies against human
sPLA2 were used as capture and detection
antibodies, respectively. Results were compared with those obtained
with culture medium from HepG2 cells stimulated
with human IL-6, as this medium contains significant amounts of
sPLA2. The amount of sPLA2
in this medium was assessed by comparison with purified recombinant
human sPLA2. The lower limit of detection was 0.1 ng/ml. Normal values are <5 ng/ml.
Statistical analysis.
Patients were classified into groups
depending on presence of clinical focus of infection and culture
results: no positive cultures; positive local cultures only, including
specific stains for fungal (n = 13) or tuberculous
(n = 1) infections; and positive blood cultures,
including one patient with malaria parasitemia. These groups were
considered to reflect the degree of microbial invasion. Groups were
compared for daily and peak values among the daily plasma levels of
circulating variables, using Kruskal-Wallis tests. The
2 test with Yates' correction was used for
binomial variables. The Spearman rank correlation coefficient
rs (if above 0.35 or below
0.35) was
used to describe relations between continuous variables. Receiver
operating characteristic (ROC) curves, plotting sensitivity versus
1
specificity, were made to evaluate the diagnostic performance
for cultures of the clinical variables and inflammatory mediators at
various cutoff points. An area under the curve (AUC) closer to 1 indicates greater diagnostic power, while an AUC of 0.5 denotes no
diagnostic potential. The optimum cutoff value for maximum sensitivity
and specificity was calculated. Multiple logistic regression (forward
stepwise method, on the basis of likelihood ratio) was used to evaluate
the contribution of inflammatory mediators to clinical variables in the
prediction of microbiologically confirmed infection. The Hosmer
Lemeshow test was used to verify adequate calibration, as indicated by a P value of >0.05. Sensitivity, specificity, positive
and negative predictive values, and likelihood ratio were calculated
according to standard formulae. Values of continuous variables were
expressed as median and range. For graphic presentation, data
were summarized by mean and standard deviations. A P value
of <0.05 was considered statistically significant.
 |
RESULTS |
Patient characteristics.
Table 1
describes patient characteristics. Of the 300 patients included, 212 had a clinical focus of infection and 133 (44%) had positive cultures.
In the 53 patients with positive blood cultures, 27 had positive local
cultures. The presence of a clinical focus predicted positive cultures
(P < 0.005), since only 27 patients with the latter
did not have a clinical infection focus. The presence of a clinical
focus of infection also predicted positive blood cultures
(P < 0.005), since only seven bacteremic patients did not have a clinical infection focus. The mortality was higher when a
clinical focus was present and cultures proved positive. Subgroups
according to clinical focus of infection and culture results were
comparable, except for younger age in patients without a clinical focus
of infection but with positive blood cultures and except for the
relative predominance of women and presence of diabetes mellitus among
patients with a clinical focus of infection and positive blood
cultures. The time elapsed between onset of fever and inclusion was
somewhat shorter among patients with a clinical focus of infection who
later proved to have positive blood cultures. Table
2 describes clinical foci and associated microorganisms. It is shown that most patients with negative cultures had respiratory and gastrointestinal infections. Most patients with
positive local cultures had respiratory and urinary tract infections
with gram-negative organisms, and most patients with bacteremia had
skin or subcutaneous infections with gram-positive organisms.
Clinical variables.
Table 3
describes the differences in clinical variables according to
microbiological test results in patients with a clinical focus: the
temperature was higher and leukocytosis was greater in patients with a
clinical focus and positive blood cultures. There were no differences
in initial or peak temperature and WBC counts among microbiological
groups in patients without a clinical focus of infection.
Inflammatory mediators.
Figure 1
describes the daily course and Table 4
describes the initial and peak levels of the circulating inflammatory
mediators according to the subgroups of the study. Peak levels of C3a
in plasma were above normal (>5 nmol/liter) in 279 (93%) patients, peak IL-6 plasma levels were above normal (>10 pg/ml) in 245 (82%) patients, and peak sPLA2 levels were supranormal
(>5 ng/ml) in 294 of 300 (98%) of patients. The sensitivity for
prediction of positive blood cultures varied between 97 and 100%, at
specificities varying between 2 and 21%. Both in patients without and
in those with a clinical infection focus, the C3a and IL-6 levels were higher when cultures, particularly those of blood, later proved positive. Daily and peak levels of inflammatory mediators did not
differ according to the focus of infection or to the Gram stain result
of the associated microorganism. Furthermore, the daily or peak levels
of mediators did not differ among patients with bacteremia with pure
gram-positive (n = 26) or gram-negative (n = 23) bacteria.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 1.
Course of mean levels (error bars, standard deviations)
in plasma of inflammatory mediators, complement C3a, IL-6, and
sPLA2, in patients without (n = 167)
( ) and with (n = 133) ( ) positive (local and
blood) cultures, at inclusion (day 1) and daily for two days thereafter
(days 2 and 3). Symbols for comparison between groups: *,
P < 0.05; **, P < 0.01;
***, P < 0.005.
|
|
Predictive value for positive local and blood cultures.
The
AUC for the ROC curve for prediction of positive local and blood
cultures was 0.60 for peak temperature (P < 0.005) and 0.59 for peak WBC (P < 0.01). For peak C3a the AUC was
0.60 (P < 0.005), for peak IL-6 it was 0.63 (P < 0.001), and for peak sPLA2
it was 0.61 (P < 0.001). The AUC of the ROC curve for
prediction of positive blood cultures for peak temperature was 0.68 (P < 0.001), while for peak WBC count it was 0.56 (P < 0.05) and lower than those for peak IL-6 and peak
C3a (P < 0.05). Indeed, the AUC of the ROC curve for
peak C3a was 0.69, that for peak IL-6 was 0.70, and that for
sPLA2 was 0.67 (Fig.
2) (for all, P < 0.001). This indicates that the predictive values of clinical variables and
mediator levels were higher for prediction of positive blood cultures
than for prediction of positive local cultures and that mediator levels
were superior to some clinical variables in this respect. The
predictive value of optimum cutoff values of clinical and mediator
variables for positive blood cultures is shown in Table
5. The presence of a clinical focus of
infection had a high positive predictive value, while the clinical and
inflammatory variables had similar, relatively low positive but high
negative predictive values.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 2.
ROC curves of mediator concentrations in plasma for
positive blood cultures. The AUC for peak C3a was 0.69, that for peak
IL-6 was 0.70, and that for peak sPLA2 was 0.67 (for all,
P < 0.001).
|
|
Correlations and logistic regression.
Correlations on
days 1, 2, and 3 between IL-6 and sPLA2 were
0.43, 0.44, and 0.44 (P < 0.001), respectively. There
were no correlations above 0.35 or below
0.35 for clinical variables versus mediators or between mediators on either day of the study.
Multiple logistic regression was done to evaluate the contribution of
mediator levels to clinical variables in predicting
positive (blood)
cultures. If combined with clinical signs (presence
of a clinical focus
of infection, peak temperature and WBC counts
[for all,
P < 0.05]), the peak C3a, IL-6, and
sPLA
2 did not contribute
to prediction of a
positive culture. However, if combined with
clinical signs (presence of
a clinical focus of infection and
peak temperature [for both,
P < 0.05]) both peak C3a and IL-6
independently
contributed (
P < 0.05) to prediction of positive
blood
cultures (81% correct; sensitivity, 17%; specificity, 98%;
positive
predictive value, 60%; negative predictive value, 85%;
Hosmer
Lemeshow
P = 0.83; X
2 = 4.3; df = 8), while peak WBC count and
sPLA
2 appeared not to
contribute independently.
Otherwise, the latter model had an area
under the ROC curve of 0.76. This indicates that the inflammatory
mediators may contribute to
clinical signs and symptoms in predicting
positive blood cultures, even
before results of the latter are
reported.
 |
DISCUSSION |
This study suggests that, in febrile patients, the degree of
microbial invasion determines the height of the systemic host response,
which is better reflected by circulating inflammatory mediators, in
particular C3a and IL-6, than by commonly used clinical variables, such
as fever and WBC counts. Conversely, circulating mediators may
help predict later-reported positive blood cultures better than or as
well as some simple clinical variables. This is important, since
bacteremia may worsen patient outcome and early appropriate empirical
antibiotic therapy may save lives (21, 33).
The frequencies of clinical foci of infection (71%) and of positive
blood cultures (18%) in our study agree with previous reports
(33). The latter also indicate that the prediction of bacteremia on the basis of clinical variables is hard (3-5, 9, 13, 33). For instance, other authors described that the area under the ROC curve of multivariate models of clinical variables was
about 0.70 and commonly lower (3-5, 33). That clinical variables may only poorly relate to inflammatory mediators such as IL-6
has been suggested before (8, 9, 24, 28, 29). Hence, the
clinical signs of an inflammatory host response may relate to
inflammatory mediators other than those studied here, including perhaps
tumor necrosis factor and IL-1. The many recent anti-inflammatory
intervention studies for improving outcome from sepsis have failed,
partly because of inclusion of noninfected patients and the too-late
inclusion of patients already in severe sepsis and shock (1,
25). Nevertheless, there was a trend for improved survival in
patients with markedly elevated IL-6 concentrations at baseline
(25). Our study suggests that inflammatory cytokines are
already released in febrile patients before positive reports of
microbiological cultures and development of severe septic shock. Hence,
IL-6 levels, if available at an early stage, might help to stratify
patients in future studies for treatment of microbial infection at an
early stage.
The local host response to microbial infection may include mechanisms
to compartmentalize infection and prevent systemic spread, and may
thereby contribute to survival. Release of inflammatory mediators into
the circulation reflects a systemic response that may, as supported by
our study, be associated with systemic spread of the microbial
infection. In patients with bacterial meningitis or pneumonia,
inflammatory mediators are elevated in cerebrospinal fluid and
bronchoalveolar lavage, respectively, whereas a rise in blood levels is
frequently associated with bacteremia (10, 19, 31).
Furthermore, blood levels of several inflammatory mediators are
elevated during sepsis, particularly when associated with shock and a
poor outcome, but an association with positive blood cultures has
hardly been found or stressed before (6-8, 15, 23, 24,
27-30). In contrast, in patients in emergency departments
suspected of a microbial infection, circulating inflammatory mediators
may be better predictive of subsequently documented microbial
infection, particularly bacteremia, than a set of clinical signs
(28, 29), in line with our study of hospitalized patients. In febrile neutropenic patients, elevated circulating IL-6 (and IL-8)
also predicted microbial infection (9). The level of IL-6
in plasma may predict sepsis in neonates better than clinical signs,
circulating IL-1 receptor antagonist, and CRP (20). In critically ill surgical patients, circulating IL-6, and to a lesser extent CRP, had predictive value for nosocomial infection
(13). In critically ill patients with clinical signs of an
inflammatory response, circulating complement activation product C3a
and IL-6 (and procalcitonin) were predictive of positive local and/or
blood cultures (27).
The systemic levels of the inflammatory mediators have been suggested
to relate to patient morbidity and mortality during sepsis and shock
(6-8, 11, 12, 16, 17, 23, 24, 29, 30, 32). We chose to
determine levels of C3a in plasma because complement activation is
thought to play a central role in the pathogenesis of severe sepsis and
septic shock through, among others, activation of neutrophils
(17). Levels of IL-6 in plasma were measured because this
cytokine is thought to have a central signaling function in the
inflammatory response to microbial infection, i.e., induction of the
acute-phase reaction. An elevated level of IL-6 in plasma has been
suggested to predict shock and outcome in patients with established
sepsis (6-8, 11, 18, 24, 29). The levels of other
cytokines, such as tumor necrosis factor or IL-1, were not determined
because of poorer predictive value than of IL-6 for the presence,
course, and outcome of severe microbial infections, among others
related to the often transient nature of their release and the
potential to induce natural inhibitors (6-8, 15, 20, 23, 24,
31). The value of proximal versus distal mediators in the
inflammatory network, including neutrophil degranulation products,
procalcitonin, and CRP, remains controversial, but studies suggest
somewhat better predictive power of the proximal mediators (5, 9,
13, 20, 26, 27, 30). In any case, the concentration in blood of
the distal mediator sPLA2 was of somewhat less
predictive value than the proximal mediators C3a and IL-6 in our
febrile patients, but the value of the latter may be similar to those
of neutrophilic products and procalcitonin (5).
The relation between sPLA2 and IL-6 may indicate
a common source and stimulus for release, including production by
macrophages and neutrophils triggered by bacterial products.
Alternatively, sPLA2 may originate from the liver
upon stimulation by IL-6, and others have found a fair relation of
plasma levels with CRP, also originating from the liver following IL-6
stimulation, during sepsis (8, 32). Therefore,
sPLA2 can also be regarded as an acute-phase
reactant. sPLA2 contributes to release of
eicosanoids and platelet activating factor, by acting on cell membranes
and thereby contributing to tissue damage, and may activate primed neutrophils, but its activity may be inhibited by C3a
(14). Alternatively, sPLA2 and CRP
may localize together on damaged plasma membranes, thereby activating
complement, so that the elevated C3a level in febrile patients with
microbial infection does not necessarily indicate complement activation
directly by microbial products (32). The
sPLA2 concentration in blood, nevertheless, related more to IL-6 than to C3a in our patients.
That the inflammatory mediator levels were also elevated above normal
in some febrile patients without microbial infection can be caused by
an underestimation of the rate of microbial infections following prior
antibiotic therapy, even though the latter was not more common in
patients with negative microbiological test results. Nevertheless,
positive blood cultures were found more often when the interval between
onset of fever and inclusion was relatively short. Furthermore, the
predictive values reported in this study do not suggest that taking
specimens for culture in febrile patients can be omitted, even though,
at sensitivities of supranormal values exceeding 97%, normal values of
the mediators missed at maximum 2 of 53 (4%) cases of positive blood
cultures. Our study also does not solve the question of whether it is
safe to withhold antibiotic treatment in patients with normal levels of mediators.
In conclusion, our study suggests that the systemic host response to
infection is a marker of the degree of microbial invasion, rather than
the focus and type of microbial infection, at an early stage in
patients with fever. Circulating complement activation products and
IL-6 may help to predict microbial bloodstream infection, together with
clinical signs of the inflammatory host response such as fever and
leukocytosis. A rapid bedside test may thus help guide the choice of
therapies, even before culture results are available, in future studies.
 |
ACKNOWLEDGMENT |
Financial support was provided by grant number 28-2275 from the
Dutch "Het Praeventiefonds."
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Medical
Intensive Care Unit, Academisch Ziekenhuis Vrije Universiteit, Postbus
7057, 1007 MB Amsterdam, The Netherlands. Phone: 31 20 4442342. Fax: 31 20 4442392. E-mail:
johan.groeneveld{at}azvu.nl.
 |
REFERENCES |
| 1.
|
Abraham, E.
1999.
Why immunomodulatory therapies have not worked in sepsis.
Intens. Care Med.
25:556-566[CrossRef][Medline].
|
| 2.
|
American College of Chest Physicians-Society of Critical Care Medicine Consensus Conference.
1992.
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.
Crit. Care Med.
20:864-875[Medline].
|
| 3.
|
Bates, D. W.,
K. Sands,
E. Miller,
P. N. Lanken,
P. L. Hibberd,
P. S. Graman,
J. S. Schwarts,
K. Kahn,
D. R. Snydman,
J. Parsonnet,
R. Moore,
E. Black,
B. L. Jonhson,
A. R. Jha, and R. Platt.
1997.
Predicting bacteremia in patients with sepsis syndrome.
J. Infect. Dis.
176:1538-1551[Medline].
|
| 4.
|
Bossink, A. W. J.,
A. B. J. Groeneveld,
C. E. Hack, and L. G. Thijs.
1999.
The clinical host response to microbial infection in medical patients with fever.
Chest
116:380-390[Abstract/Free Full Text].
|
| 5.
|
Bossink, A. W. J.,
A. B. J. Groeneveld,
C. E. Hack, and L. G. Thijs.
1999.
Prediction of microbial infection and mortality in medical patients with fever: plasma procalcitonin, neutrophilic elastase- 1-antitrypsin, and lactoferrin compared with clinical variables.
Clin. Infect. Dis.
29:398-407[Medline].
|
| 6.
|
Calandra, T.,
J. Gerain,
D. Heumann,
J.-D. Baumgartner, and M. P. Glauser.
1991.
High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines.
Am. J. Med.
91:23-29[CrossRef][Medline].
|
| 7.
|
Casey, L. C.,
R. A. Balk, and R. C. Bone.
1993.
Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome.
Ann. Intern. Med.
119:771-778[Abstract/Free Full Text].
|
| 8.
|
Damas, P.,
D. Ledoux,
M. Nys,
Y. Vrindts,
D. De Groote,
P. Franchimont, and M. Lamy.
1992.
Cytokine serum level during severe sepsis in human IL-6 as a marker of severity.
Ann. Surg.
215:356-362[Medline].
|
| 9.
|
De Bont, E. S. J. M.,
E. Vellenga,
J. C. J. M. Swaanenburg,
V. Fidler,
P. J. Visser-van Brummen, and W. A. Kamps.
1999.
Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia.
Br. J. Haematol.
107:375-380[CrossRef][Medline].
|
| 10.
|
Dehoux, M. S.,
A. Boutten,
J. Ostinelli,
N. Seta,
M. C. Dombret,
B. Crestani,
M. Deschenes,
J. L. Trouillet, and M. Aubier.
1994.
Compartmentalized cytokine production within the human lung in unilateral pneumonia.
Am. J. Respir. Crit. Care. Med.
150:710-716[Abstract].
|
| 11.
|
Dofferhoff, A. S. M.,
V. J. J. Bom,
H. G. de Vries-Hospers,
J. van Ingen,
J. van der Meer,
B. P. C. Hazenberg,
P. O. M. Mulder, and J. Weits.
1992.
Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans.
Crit. Care Med.
20:185-192[Medline].
|
| 12.
|
Endo, S.,
K. Inada, and H. Nakae.
1995.
Plasma levels of type II phospholipase A2 and cytokines in patients with sepsis.
Res. Commun. Mol. Pathol. Pharmacol.
90:413-421[Medline].
|
| 13.
|
Fassbender, K.,
H. Pargger,
W. Müller, and W. Zimmerli.
1993.
Interleukin-6 and acute-phase protein concentrations in surgical intensive care unit patients: diagnostic signs in nosocomial infection.
Crit. Care Med.
21:1175-1180[Medline].
|
| 14.
|
Gijon, M. A.,
C. Pérez,
E. Méndez, and M. Sánchez Crespo.
1995.
Phospholipase A2 from plasma of patients with septic shock is associated with high-density lipoproteins and C3 anaphylatoxin: some implications for its functional role.
Biochem. J.
306:167-175.
|
| 15.
|
Gogos, C. A.,
E. Drosou,
H. P. Bassaris, and A. Skoutelis.
2000.
Pro- versus antiinflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options.
J. Infect. Dis.
181:176-180[CrossRef][Medline].
|
| 16.
|
Guidet, B.,
O. Piot,
J. Masliah,
V. Barakett,
E. Maury,
G. Bereziat, and G. Offenstadt.
1996.
Secretory non-pancreatic phospholipase A2 in severe sepsis: relation to endotoxin, cytokines and thromboxane B2.
Infection
24:103-108[CrossRef][Medline].
|
| 17.
|
Hack, C. E.,
J. H. Nuijens,
R. J. F. Felt-Bersma,
W. O. Schreuder,
A. J. M. Eerenberg-Belmer,
J. Paardekoper,
W. Bronsveld, and L. G. Thijs.
1989.
Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis.
Am. J. Med.
86:20-26[CrossRef][Medline].
|
| 18.
|
Hack, C. E.,
E. R. de Groot,
R. J. F. Felt-Bersma,
J. H. Nuijens,
R. J. M. Strack van Schijndel,
A. J. M. Eerenberg-Belmer,
L. G. Thijs, and L. A. Aarden.
1989.
Increased plasma levels of interleukin-6 in sepsis.
Blood
74:1704-1710[Abstract/Free Full Text].
|
| 19.
|
Kragsbjerg, P.,
I. Jones,
T. Vikerfors, and H. Holmberg.
1995.
Diagnostic values of blood cytokine concentrations in acute pneumonia.
Thorax
50:1253-1257[Abstract/Free Full Text].
|
| 20.
|
Küster, H.,
M. Weiss,
A. E. Willeitner,
S. Detlieffsen,
I. Jeremias,
J. Zbojan,
R. Geiger,
G. Lipowsky, and G. Simbruner.
1998.
Interleukin-1 receptor antagonist and interleukin-6 for early diagnosis of neonatal sepsis 2 days before clinical manifestation.
Lancet
352:1271-1277[CrossRef][Medline].
|
| 21.
|
Leibovici, L.,
A. Samra,
H. Konigsberger,
M. Drucker,
S. Ashkenazi, and S. D. Pitlik.
1995.
Long-term survival following bacteremia or fungemia.
JAMA
274:807-812[Abstract/Free Full Text].
|
| 22.
|
McGowan, J. E.,
R. C. Rose,
N. F. Jacobs,
D. R. Schaberg, and R. W. Haley.
1987.
Fever in hospitalized patients. With special reference to the medical service.
Am. J. Med.
82:580-586[CrossRef][Medline].
|
| 23.
|
Pinsky, M. R.,
J.-L. Vincent,
J. Deviere,
M. Alegre,
R. J. Kahn, and E. Dupont.
1993.
Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality.
Chest
103:565-575[Abstract/Free Full Text].
|
| 24.
|
Presterl, E.,
T. Staudinger,
M. Pettermann,
A. Lassnigg,
H. Burgmann,
S. Winkler,
M. Frass, and W. Graninger.
1997.
Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis.
Am. J. Respir. Crit. Care Med.
156:825-832[Abstract/Free Full Text].
|
| 25.
|
Reinhart, K.,
C. Wiegand-Löhnert,
F. Grimminger,
M. Kaul,
S. Withington,
D. Treacher,
J. Eckart,
S. Willatts,
C. Bouza,
D. Krausch,
F. Stockenhuber,
J. Eiselstein,
L. Daum, and J. Kempeni.
1996.
Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
Crit. Care Med.
24:733-742[CrossRef][Medline].
|
| 26.
|
Rintala, E. S., and T. J. Nevalainen.
1993.
Group II phospholipase A2 in sera of febrile patients with microbiologically or clinically documented infections.
Clin. Infect. Dis.
17:864-870[Medline].
|
| 27.
|
Selberg, O.,
H. Hecker,
M. Martin,
A. Klos,
W. Bautsch, and J. Köhl.
2000.
Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6.
Crit. Care Med.
28:2793-2798[CrossRef][Medline].
|
| 28.
|
Takala, A.,
I. Jousela,
K. T. Olkkola,
S.-E. Jansson,
M. Leirisalo-Repo,
O. Takkunen, and H. Repo.
1999.
Systemic inflammatory response syndrome without systemic inflammation in acutely ill patients admitted to hospital in a medical emergency.
Clin. Sci.
96:287-295[Medline].
|
| 29.
|
Terregino, C. A.,
B. L. Lopez,
D. J. Karras,
A. J. Killian, and G. K. Arnold.
2000.
Endogenous mediators in emergency department patients with presumed sepsis: are levels associated with progression to severe sepsis and death?
Ann. Emerg. Med.
35:26-34[CrossRef][Medline]l.
|
| 30.
|
Uhl, W.,
H. G. Beger,
G. Hoffman,
E. Hanisch,
A. Schild,
C. Waydhas,
E. Entholzner,
K. Müller,
W. Kellerman,
M. Vogeser,
M. Zügel,
E. W. Busch, and M. W. Büchler.
1995.
A multicenter study of phospholipase A2 in patients in intensive care units.
J. Am. Coll. Surg.
180:323-331[Medline].
|
| 31.
|
Van Deuren, M.,
J. van der Ven-Jongekrijg,
A. K. Bartelink,
R. van Dalen,
R. W. Sauerwein, and J. W. van der Meer.
1995.
Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections.
J. Infect. Dis.
172:433-439[Medline].
|
| 32.
|
Wolbink, G.-J.,
A. W. J. Bossink,
A. B. J. Groeneveld,
M. C. M. de Groot,
L. G. Thijs, and C. E. Hack.
1998.
Complement activation in patients with sepsis is in part mediated by C-reactive protein.
J. Infect. Dis.
177:81-87[Medline].
|
| 33.
|
Yehezkeli, Y.,
S. Subah,
G. Elhanan,
R. Raz,
A. Porter,
A. Regev, and L. Leibovici.
1996.
Two rules for early prediction of bacteremia: testing in a university and a community hospital.
J. Gen. Intern. Med.
11:98-103[Medline].
|
Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1189-1195, Vol. 8, No. 6
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.6.1189-1195.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Tavares, E., Maldonado, R., Ojeda, M. L., Minano, F. J.
(2005). Circulating Inflammatory Mediators during Start of Fever in Differential Diagnosis of Gram-Negative and Gram-Positive Infections in Leukopenic Rats. CVI
12: 1085-1093
[Abstract]
[Full Text]
-
Tacx, A N, Groeneveld, A B J, Hart, M H, Aarden, L A, Hack, C E
(2003). Mannan binding lectin in febrile adults: no correlation with microbial infection and complement activation. J. Clin. Pathol.
56: 956-959
[Abstract]
[Full Text]